AcelRx Pharmaceuticals aims to price public offering of common stock

Proceeds of sale will be used by the company to support operations

By Devika Patel

Knoxville, Tenn., Nov. 20 - AcelRx Pharmaceuticals, Inc. intends to price a public offering of its common stock, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission.

The deal has a 30-day greenshoe option.

Proceeds will be used to support operations.

Based in Redwood City, Calif., AcelRx is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.